SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc. provides update on data from its ongoing Phase 1 Clinical Trial of TGN-S11 in patients with Stage 4 HPV-associated cancers.
Home › RSS › Toragen, Inc. Provides Update on Data from Ongoing Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® (pembrolizumab) in Patients with Stage 4 Human Papillomavirus-Associated Cancers